@prefix this: . @prefix sub: . @prefix drugbank: . @prefix np: . @prefix mondo: . @prefix pav: . @prefix infores: . @prefix xsd: . @prefix ntemplate: . @prefix orcid: . @prefix rdfs: . @prefix pmid: . @prefix ncit: . @prefix rdf: . @prefix biolink: . @prefix prov: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubInfo; a np:Nanopublication . } sub:assertion { drugbank:DB01267 a biolink:Drug; rdfs:label "Paliperidone"; biolink:category biolink:Drug . mondo:0004985 a biolink:Disease; rdfs:label "Bipolar disorder"; biolink:category biolink:Disease . sub:association rdf:object mondo:0004985; rdf:predicate biolink:treats; rdf:subject drugbank:DB01267; a biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation; rdfs:label "When we asked about the long-term treatment of BD, after having excluded from the analyses the 3 SGAs with a European indication for maintenance BD treatment (aripiprazole, olanzapine, and quetiapine), asenapine was considered either “highly appropriate” or “appropriate” by 44.6% of the respondents, while other off-label SGAs (clozapine, paliperidone, risperidone, ziprasidone) were mostly considered inappro- priate for maintenance bipolar treatment"; biolink:aggregator_knowledge_source infores:knowledge-collaboratory; biolink:category biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation; biolink:has_population_context sub:context; biolink:publications pmid:31291215; biolink:relation ncit:C94303 . sub:context a biolink:Cohort; rdfs:label "Adults"; biolink:category biolink:Cohort . } sub:provenance { sub:assertion prov:wasAttributedTo orcid:0000-0002-7641-6446 . } sub:pubInfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCR9fz0fKCdWOWC+pxhkQhEM/ppbdIYe5TLSdj+lJzSlv9mYBaPgrzVezSwwbmhlHBPDZa4/vHycU315BdmUGq+pXllp9+rWFfrb+kBJwhZjpG6BeyyXBsRFz4jmQVxl/ZYHilQTh/XalYzKkEAyTiEMPee4Kz61PaWOKH24CsnOQIDAQAB"; npx:hasSignature "E+SD0mXhpjqwIv3rZPiiHQK6i446aXe+wxXUkS2f+oZdR7ir7P77p4wJb3Rf8LYsuSb5+zpd9E2VIhwCeRNp+pDCeSRgTwO28nHhUH5oFkNkL6Qnu5qUcrlGtTh9dAzhQRe5QMC6YAQDWjDj/ArUQzZsmFkXdZkLOoHelz/lEeQ="; npx:hasSignatureTarget this: . this: prov:generatedAtTime "2022-09-16T11:50:09.445682"^^xsd:dateTime; prov:wasAttributedTo orcid:0000-0002-1501-1082; ntemplate:wasCreatedFromTemplate . biolink: pav:version "2.3.0" . }